Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New Platform to Accelerate COVID-19 Tests into Real-World Use

By LabMedica International staff writers
Posted on 25 Jun 2020
Testing for coronavirus infection could become quicker, more convenient and more accurate, following the launch of a multi-centre national program of research in the UK that will evaluate how new diagnostic tests perform in hospitals, general practices and care homes.

The COVID-19 National DiagnOstic Research and Evaluation Platform (CONDOR) will create a single national route for evaluating new diagnostic tests in hospitals and in community healthcare settings. More...
The research program will bringing together experts who are highly experienced in evaluating diagnostic tests and generating the robust evidence required for a test to be used in the NHS.

Jointly led by the University of Oxford (Oxford, UK) and Manchester University NHS Foundation Trust (Manchester, UK), the program will put the many tests developed by the life sciences industry to either detect current coronavirus infection or to find out if someone has previously been infected through their paces in hospital, general practice, and care home environments. The research will assess multiple diagnostic tests at once at sites across the UK and can be adapted to add in new tests as they become available.

“Right now, there’s a critical gap in how we road-test new diagnostics for COVID-19. By robustly evaluating these diagnostics in health and care settings, the CONDOR program will help the government and clinicians to understand the real-world accuracy of these tests in patients presenting with COVID-19 symptoms in the NHS,” said co-primary investigator Professor Gail Hayward, Associate Professor at the University of Oxford’s Nuffield Department of Primary Care Health Sciences, and Deputy Director of the NIHR Community Healthcare MedTech and IVD Co-operative.

Related Links:
University of Oxford
Manchester University NHS Foundation Trust



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.